345 PARK AVENUE SOUTH, NEW YORK, NY
Protara Therapeutics Reports 68% Six-Month CR Rate in BCG-Unresponsive Patients
Financial Results, Press Release
Interim Safety and Tolerability of TARA - 002 in Patients with BCG - Naive and Unresponsive High - grade Non - muscle Invasive Bladder Cancer in ADVANCED - 2
Protara Therapeutics Completes $5.75 Public Offering of 13,043,479 Shares
Protara Therapeutics Enters Underwriting Agreement for $75 Million Offering
ADVANCED - 2: Preliminary Efficacy and Safety Data in BCG - naïve Participants with High - grade Non - muscle Invasive Bladder Cancer
Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
Announces Third Quarter 2025 Financial Results and Provides Business Update
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
Prospectus filed pursuant to Rule 424(b)(7)